Condition
Neuromyelitis Optica Spectrum Disorder Attack
Total Trials
5
Recruiting
2
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
20%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
0
Data Visualizations
Phase Distribution
3Total
P 2 (2)
P 4 (1)
Trial Status
Recruiting2
Terminated1
Withdrawn1
Unknown1
Clinical Trials (5)
Showing 5 of 5 trials
NCT07410039Phase 4RecruitingPrimary
Therapy in the Acute Phase of NMOSD: A Multicenter Prospective Real-World Study
NCT07184840Phase 2RecruitingPrimary
Eculizumab For the Acute Attack of Neuromyelitis Optica Spectrum Disorder
NCT06673394Phase 2WithdrawnPrimary
Eculizumab For Acute Attack of Neuromyelitis Optica Spectrum Disorder
NCT04131764Terminated
Diagnosis of ON With or Without MS or NMOSD
NCT05605951Unknown
Acute Optic Neuritis Network: an International Study That Invesitages Subjects With a First-ever Episode of Acute Inflammation of the Optic Nerve
Showing all 5 trials